How long can you live taking the targeted drug Osimertinib?

Lung cancer is the deadliest form of cancer and often shows no symptoms in its early stages, meaning diagnosis can easily be missed. Even if lung cancer patients have their tumors removed or receive chemotherapy, the five-year survival rate is currently only about 25%. The once-daily drug Osimertinib reduces the risk of death in lung cancer patients by 51%. The trial included 682 patients with non-small cell lung cancer (NSCLC), all of whom had undergone cancer surgery, and were then randomly assigned to take either a daily placebo tablet or an 80 mg dose of osimertinib. New research results suggest that taking osimertinib after surgery for some patients with early-stage lung cancer may significantly improve their odds of survival.